HS
ITOS

HighVista Strategies’s iTeos Therapeutics ITOS Stock Holding History

HighVista Strategies’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-18,913
Closed -$390K – 120
2022
Q2 		$390K Sell
18,913
-3,899
-17% -$92.5K 0.24% 82
2022
Q1 		$734K Sell
22,812
-11,675
-34% -$424K 0.47% 61
2021
Q4 		$1.61M Buy
+34,487
New +$1.15M 1.28% 20
2021
Q2 		– Sell
-19,804
Closed -$677K – 129
2021
Q1 		$677K Buy
19,804
+1,924
+11% +$69.5K 0.5% 45
2020
Q4 		$605K Buy
+17,880
New +$473K 0.39% 64

Other funds holding ITOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

HighVista Strategies's ITOS Position: Q3 2022 in Review

HighVista Strategies sold out of iTeos Therapeutics (ITOS) in Q3 2022, closing a stake of 18,913 shares — an estimated $390K sold.

HighVista Strategies first reported a position in ITOS in Q4 2020 and held it in 5 quarters. The position peaked at $1.61M in Q4 2021. 143 funds tracked by Wall St. Rank hold ITOS as of Q3 2022.

  • HighVista Strategies reported no remaining iTeos Therapeutics position as of Q3 2022 after selling out during the quarter.
  • HighVista Strategies sold 18,913 iTeos Therapeutics shares in Q3 2022, an estimated $390K.
  • HighVista Strategies first reported a position in iTeos Therapeutics in Q4 2020 and held it in 5 quarters.
  • HighVista Strategies's iTeos Therapeutics position peaked at $1.61M in Q4 2021.
  • 143 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2022.

Based on HighVista Strategies's 13F filing for Q3 2022, filed 14 Nov 2022.